Efficacy and safety of Iranian made Deferasirox (Osveral®) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study

PURPOSE OF THE STUDY: to determine the efficacy, adverse effects and safety of a new Iranian generic product of deferasirox (Osveral®) in Iranian transfusion dependent major thalassemic (TD-MT) patients. METHODS: In 9 main thalassemia treatment centers, all of TD-MT patients (aged ≥2 yrs) with serum...

Descripción completa

Detalles Bibliográficos
Autores principales: Eshghi, P., Farahmandinia, Z., Molavi, M., Naderi, M., Jafroodi, M., Hoorfar, H., Davari, K., Azarkeivan, A., Keikhaie, B., Ansari, S., Arasteh, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232111/
https://www.ncbi.nlm.nih.gov/pubmed/22615664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232111/
https://www.ncbi.nlm.nih.gov/pubmed/22615664

Ejemplares similares